Topical treatment of impetigo caused by methicillinsusceptible Staphylococcus aureus or Streptococcus pyogenes.
Interferes with bacterial protein synthesis at the level of the 50S ribosome. Therapeutic Effects: Bacteriostatic action against susceptible organisms.
Adverse Reactions/Side Effects
Derm: application site irritation.
PHYSICAL THERAPY IMPLICATIONS
Examination and Evaluation
Assess the area being treated to help determine if drug therapy is successful in resolving skin conditions.
Monitor any new or increased skin reactions at the site of application, including rash, itching, burning, or other suspicious skin lesions. Report severe or unusual skin reactions to the physician.
Always wash hands thoroughly and disinfect equipment (whirlpools, electrotherapeutic devices, treatment tables, and so forth) to help prevent the spread of infection. Use universal precautions or isolation procedures as indicated for specific patients.
Check that the patient and family or caregivers understand topical application procedures, and adhere to the recommended dosing schedule.
Instruct patient with skin lesions to avoid itching or scratching the affected area. Patients should avoid contact with other individuals (e.g., other athletes) during the active phase of the infection.
Absorption: Minimal systemic absorption.
Metabolism and Excretion: Small amounts absorbed are extensively metabolized.
|ROUTE ||ONSET ||PEAK ||DURATION |
|topical ||unknown ||unknown ||12 hr |
Contraindicated in: No contraindications.
Use Cautiously in: OB: Use only in pregnancy when maternal benefit outweighs fetal risk; safe use during lactation not established; Pedi: Safe use in children <9 mo not established.
Topical (Adults and Children ≥9 mo): Apply thin layer to affected area (up to 100 cm2 in adults or 2% total body area in children) bid for 5 days.
Ointment: 10 mg/g in 5-, 10-, and 15-g tubes.